{"filing":{"accession_number":"0001193125-26-326785","cik":"0001055726","ticker":"INO","company_name":"INOVIO PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-29","primary_document":"d253972d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312526326785/d253972d8k.htm"},"events":[{"id":22788,"run_id":20622,"accession_number":"0001193125-26-326785","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Inovio entered into an underwriting agreement on July 29, 2026 to issue 21,052,632 shares of common stock and warrants to purchase 42,105,264 additional shares in a registered public offering at $0.95 per share, with expected gross proceeds of approximately $20.0 million and net proceeds of approximately $18.3 million. The offering was priced on July 29, 2026 with expected closing on July 31, 2026.","company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22838,"accession_number":"0001193125-26-326785","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Inovio entered into an underwriting agreement on July 29, 2026 to issue 21,052,632 shares of common stock and warrants to purchase 42,105,264 additional shares in a public offering at $0.95 per share, with expected net proceeds of approximately $18.3 million. This is a registered public offering of equity securities that will dilute existing shareholders. While technically registered (via Form S-3), the scale and warrant structure (2:1 warrant-to-share ratio) represent material dilution typical of equity capital raises by smaller biotechnology companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:26:00.537861+00:00","company_name":"","ticker":null,"filing_date":""},{"id":22839,"accession_number":"0001193125-26-326785","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"INOVIO announced and priced an underwritten public offering of 21,052,632 shares of common stock and accompanying warrants to purchase 42,105,264 shares at $0.95 per unit, with expected gross proceeds of approximately $20.0 million. This is a registered public offering of equity securities that will dilute existing shareholders. The exhibits confirm the offering was announced on July 29, 2026 and priced the same day, with expected closing on July 31, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:26:00.537861+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22838,"accession_number":"0001193125-26-326785","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Inovio entered into an underwriting agreement on July 29, 2026 to issue 21,052,632 shares of common stock and warrants to purchase 42,105,264 additional shares in a public offering at $0.95 per share, with expected net proceeds of approximately $18.3 million. This is a registered public offering of equity securities that will dilute existing shareholders. While technically registered (via Form S-3), the scale and warrant structure (2:1 warrant-to-share ratio) represent material dilution typical of equity capital raises by smaller biotechnology companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:26:00.537861+00:00","company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","filing_date":"2026-07-31"},{"id":22839,"accession_number":"0001193125-26-326785","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"INOVIO announced and priced an underwritten public offering of 21,052,632 shares of common stock and accompanying warrants to purchase 42,105,264 shares at $0.95 per unit, with expected gross proceeds of approximately $20.0 million. This is a registered public offering of equity securities that will dilute existing shareholders. The exhibits confirm the offering was announced on July 29, 2026 and priced the same day, with expected closing on July 31, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:26:00.537861+00:00","company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","filing_date":"2026-07-31"}]}